Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (10) near the Bid: 451 vs 8918 OI

Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (10) near the Bid: 451 @ $21.401 vs 8918 OI; Ref=$191.175

Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (6) near the Bid: 500 vs 8918 OI

Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (6) near the Bid: 500 @ $21.401 vs 8918 OI; Ref=$191.14

Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (24) near the Bid: 252 vs 8918 OI

Johnson & Johnson Option Alert: Oct 17 $170 Calls Sweep (24) near the Bid: 252 @ $21.4 vs 8918 OI; Ref=$191.1

Johnson & Johnson Option Alert: Jan 16 $185 Calls at the Ask: 1400 vs 4429 OI

Johnson & Johnson Option Alert: Jan 16 $185 Calls at the Ask: 1400 @ $11.0 vs 4429 OI; Ref=$190.65

Johnson & Johnson Option Alert: Nov 14 $180 Calls at the Ask: 1300 vs 1 OI

Johnson & Johnson Option Alert: Nov 14 $180 Calls at the Ask: 1300 @ $12.5 vs 1 OI; Ref=$190.975

Johnson & Johnson Option Alert: Nov 14 $175 Calls at the Ask: 700 vs 1 OI

Johnson & Johnson Option Alert: Nov 14 $175 Calls at the Ask: 700 @ $17.2 vs 1 OI; Ref=$191.01

Johnson & Johnson Option Alert: Nov 7 $175 Calls at the Ask: 752 vs 29 OI

Johnson & Johnson Option Alert: Nov 7 $175 Calls at the Ask: 752 @ $17.0 vs 29 OI; Ref=$191.02

Johnson & Johnson

JOHNSON & JOHNSON

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Elon,Musk,Owns,Tesla,,Spacex,,X,(formerly,Twitter),,Neuralink,,Xai

News

BABA

ORCL

PLTR

TSLA

Il patrimonio del visionario imprenditore infrange ogni record. Le sue aziende stanno riscrivendo le regole della ricchezza globale.

Tesla spinge Musk verso i 500 miliardi, ma la vera sorpresa arriva da xAI e SpaceX

Displaying,Dashboard,Tracking,Market,Swings,On,Trading,Screen,,With,Colored

Equities

Markets

ASML

NFLX

RGTI

Gli indici USA chiudono positivi: Dow Jones +0,5%, Nasdaq e S&amp;P 500 in crescita. Tra i titoli più discussi: Rigetti, J&amp;J e ASML.

Rigetti, Netflix, Johnson &amp; Johnson, United Airlines, ASML: 5 azioni USA nel radar degli investitori

Johnson and Johnson-Photo by Tada Images via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

Johnson &amp; Johnson registra utili adjusted di 2,77$ per azione nel Q2 2025

Press Releases

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota

RBOT

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

Morgan Stanley

Goldman Sachs

Citigroup

Bernstein

B of A Securities

Screenshot 2025-09-23 at 9.53.22 PM

Interview

RVPH

Reviva Pharmaceuticals CEO Tells Benzinga About The Trouble With Today&#39;s Schizophrenia Drugs – And How The Company Is Fixing That

Screenshot 2025-07-10 at 8.34.03 PM

KERX

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern.

SeaStar Medical&#39;s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:51 AMOct 10, 2025	CALL	$170.00	Oct 17, 2025	5	1894	451	21	8918	SWEEP	BEARISH
10:49 AMOct 10, 2025	CALL	$170.00	Oct 17, 2025	5	1083	500	12	8918	SWEEP	BEARISH
10:49 AMOct 10, 2025	CALL	$170.00	Oct 17, 2025	5	331	252	4	8918	SWEEP	BEARISH
10:40 AMOct 10, 2025	CALL	$185.00	Jan 16, 2026	96	1401	1400	32	4429	TRADE	BULLISH
10:40 AMOct 10, 2025	CALL	$180.00	Nov 14, 2025	33	1300	1300	130000	1	TRADE	BULLISH
10:40 AMOct 10, 2025	CALL	$175.00	Nov 14, 2025	33	700	700	70000	1	TRADE	BULLISH
10:40 AMOct 10, 2025	CALL	$175.00	Nov 07, 2025	26	800	752	2759	29	TRADE	BULLISH

Comments

Johnson & Johnson

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO